{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.0","upperLimit":"87.7","value":"78.8"},{"groupId":"OG001","lowerLimit":"54.0","upperLimit":"75.5","value":"66.0"},{"groupId":"OG002","lowerLimit":"22.4","upperLimit":"51.8","value":"37.1"},{"groupId":"OG003","lowerLimit":"70.9","upperLimit":"87.2","value":"80.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"119"}],"units":"Participants"}],"description":"Probability of survival was defined as the probability of being alive at Month 12.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).","id":"OG000","title":"RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).","id":"OG001","title":"RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).","id":"OG002","title":"RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).","id":"OG003","title":"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"}],"paramType":"NUMBER","populationDescription":"SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.","reportingStatus":"POSTED","timeFrame":"Month 12","title":"Probability of Participant Survival at Month 12","type":"PRIMARY","unitOfMeasure":"probability of participants survival"}